STTK: DR3-targeted therapies show durable efficacy and low immunogenicity, with broad expansion plans
The session highlighted a differentiated approach to immune modulation by targeting DR3, with promising phase I data showing durable receptor occupancy and low immunogenicity. Clinical development is focused on Crohn's disease, with plans to expand into HS and psoriatic arthritis, and a bispecific…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.